Skip to main content

Table 5 Lung function measurements in Xuan Bai Cheng Qi and control groups before and after 10-day treatment

From: Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Lung functiona XBCQb Controlb Treatment effectd(95% CI; P value)
  Day 1 (Baseline) Day 10 (End) Mean Dc Day 1 (Baseline) Day 10 (End) Mean Dc  
FEV1 (liters)        
 FAS (122,122) 1.18 (0.41) 1.44 (0.49) 0.24 (0.29) 1.19 (0.40) 1.29 (0.47) 0.10 (0.31) 0.14 (0.06, 0.22; < .001)
 PPS (111,118) 1.20 (0.42) 1.44 (0.49) 0.24 (0.29) 1.19 (0.39) 1.29 (0.47) 0.10 (0.31) 0.13 (0.06, 0.21; .001)
FVC (liters)        
 FAS (122,122) 2.16 (0.62) 2.40 (0.67) 0.23 (0.38) 2.10 (0.58) 2.17 (0.62) 0.08 (0.48) 0.17 (0.06, 0.28; .002)
 PPS (111,118) 2.17 (0.60) 2.40 (0.65) 0.23 (0.38) 2.11 (0.57) 2.19 (0.60) 0.08 (0.48) 0.16 (0.05, 0.27; .004)
FEV1 % pred        
 FAS (122,122) 51.54 (19.49) 62.39 (19.57) 10.59 (11.76) 52.13 (19.17) 55.35 (20.59) 3.22 (10.53) 7.33 (4.58, 10.07; < .001)
 PPS (111,118) 52.60 (19.74) 63.38 (19.36) 10.49 (11.84) 52.17 (19.27) 55.56 (22.68) 3.39 (10.50) 7.20 (4.37,10.03; < .001)
  1. Abbreviations: CI confidence interval, COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in one second, FEV 1 % pred FEV1 percentage of predicted value, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, Mean D mean difference, XBCQ Xuan Bai Cheng Qi.
  2. aFAS population was 122 in the XBCQ group and 122 in the control group; PPS population was 111 in the XBCQ group and 118 in the control group.
  3. bData presented as mean (SD).
  4. c P < .01: Change between pre-treatment and post-treatment (within group difference by paired t-test).
  5. dCovariance analysis estimate with 95% confidence interval for difference.